STOCK TITAN
  1. Home
  2. News
  3. ATNF

180 Life Sciences Corp - ATNF STOCK NEWS

Welcome to our dedicated news page for 180 Life Sciences (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 180 Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 180 Life Sciences's position in the market.

News
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
180 Life Sciences Corp. (NASDAQ: ATNF) announced that it has regained compliance with the Nasdaq's Minimum Bid Price Requirement by maintaining a closing bid price of $1.00 per share for 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
Rhea-AI Summary
180 Life Sciences Corp. (ATNF) announces a 1-for-19 reverse stock split to regain Nasdaq compliance. The split will reduce outstanding shares from 11.3 million to 0.6 million, with shares trading on a split-adjusted basis from February 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
stock split
-
News
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
Rhea-AI Summary
180 Life Sciences Corp. (NASDAQ: ATNF) has engaged A.G.P./Alliance Global Partners to explore strategic alternatives to enhance shareholder value, including acquisition, merger, reverse merger, business combination, sale of assets, licensing, or other strategic transactions. The company will not disclose further developments unless approved by the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
none
News
180 Life Sciences Announces Review of Strategic Alternatives
Rhea-AI Summary
180 Life Sciences Corp. (ATNF) has initiated a process to evaluate potential strategic alternatives to maximize shareholder value. The company will consider a broad range of options, with no specific timeline for completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
none
-
News
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
Rhea-AI Summary
180 Life Sciences Corp. (NASDAQ: ATNF) announced the completion of a public offering, raising approximately $3 million. The proceeds will be used for research and development, marketing authorization application, and legal expenses. The offering includes shares of common stock and warrants at a purchase price of $0.65 per share, with immediate exercisability and expiration in 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
offering
-
News
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.71%
Tags
offering
News
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
Rhea-AI Summary
180 Life Sciences Corp. announces agreement for a clinical study on CBD uptake in pill form
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
-
News
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
Rhea-AI Summary
180 Life Sciences Corp. (NASDAQ: ATNF) seeks regulatory guidance for Conditional Marketing Authorization (CMA) for adalimumab in the treatment of early stage Dupuytren’s disease. The company plans to meet with the UK's MHRA and the US FDA to discuss requirements for obtaining marketing approval and the potential design of a Phase 3 clinical trial. Promising data from a Phase 2b trial and potential cost-effectiveness support the company's belief in the therapy's potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
none
News
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
offering
Stock ATNF logo
180 Life Sciences Corp

Nasdaq:ATNF

ATNF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ATNF Stock Data

1.26M
765.12k
3.35%
11.2%
4.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Palo Alto

About ATNF

180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.